Literature DB >> 16714725

Optimising management in Turner syndrome: from infancy to adult transfer.

M D C Donaldson1, E J Gault, K W Tan, D B Dunger.   

Abstract

Turner syndrome can be defined as loss or abnormality of the second X chromosome in at least one cell line in a phenotypic female. The condition occurs in approximately 1 in every 2000 live female births,(1) so that in the UK the prevalence for any year of life is in the region of 200 girls. The condition is much more common in utero, it being estimated that 1-2% of all conceptuses are affected, of whom only 1% will survive to term.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16714725      PMCID： PMC2082783          DOI： 10.1136/adc.2003.035907

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  82 in total

Review 1.  Four decades of growth hormone therapy for short children: what have we achieved?

Authors:  H J Guyda
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome.

Authors:  E Cacciari; L Mazzanti
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

3.  Endogenous growth hormone secretion does not correlate with growth in patients with Turner's syndrome. Italian Study Group for Turner Syndrome.

Authors:  L Cavallo; R Gurrado
Journal:  J Pediatr Endocrinol Metab       Date:  1999 Sep-Oct       Impact factor: 1.634

4.  Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function.

Authors:  D H Skuse; R S James; D V Bishop; B Coppin; P Dalton; G Aamodt-Leeper; M Bacarese-Hamilton; C Creswell; R McGurk; P A Jacobs
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

5.  Role of oestrogen therapy in the management of short stature in Turner syndrome.

Authors:  S D Chernausek; K M Attie
Journal:  Acta Paediatr Suppl       Date:  1999-12

6.  A first-generation X-inactivation profile of the human X chromosome.

Authors:  L Carrel; A A Cottle; K C Goglin; H F Willard
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

7.  Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome.

Authors:  E Rao; B Weiss; M Fukami; A Rump; B Niesler; A Mertz; K Muroya; G Binder; S Kirsch; M Winkelmann; G Nordsiek; U Heinrich; M H Breuning; M B Ranke; A Rosenthal; T Ogata; G A Rappold
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

Review 8.  Growth hormone therapy in Turner syndrome--current uncertainties and future strategies.

Authors:  M D Donaldson
Journal:  Horm Res       Date:  1997

9.  Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone.

Authors:  T C Sas; S M de Muinck Keizer-Schrama; T Stijnen; H J Aanstoot; S L Drop
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

10.  Oocyte donation in Turner's syndrome: an analysis of the factors affecting the outcome.

Authors:  G Khastgir; H Abdalla; A Thomas; L Korea; L Latarche; J Studd
Journal:  Hum Reprod       Date:  1997-02       Impact factor: 6.918
View more
  23 in total

1.  Turner syndrome with dental structural abnormalities: histological and morphostructural features by confocal laser microscopy.

Authors:  A P Cazzolla; F Riccitiello; V A La Carbonara; S Franco; M G Lacaita
Journal:  Ann Stomatol (Roma)       Date:  2013-10-24

Review 2.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

3.  Systematic review of quality of life in Turner syndrome.

Authors:  Carolina Trombeta Reis; Maíra Seabra de Assumpção; Gil Guerra-Junior; Sofia Helena Valente de Lemos-Marini
Journal:  Qual Life Res       Date:  2018-02-09       Impact factor: 4.147

4.  Growth hormone plus childhood low-dose estrogen in Turner's syndrome.

Authors:  Judith L Ross; Charmian A Quigley; Dachuang Cao; Penelope Feuillan; Karen Kowal; John J Chipman; Gordon B Cutler
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

Review 5.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

Review 6.  Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management.

Authors:  Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

7.  Metabolic impact of sex chromosomes.

Authors:  Jenny C Link; Xuqi Chen; Arthur P Arnold; Karen Reue
Journal:  Adipocyte       Date:  2013-04-01       Impact factor: 4.534

8.  Bone age is the best predictor of growth response to recombinant human growth hormone in Turner's syndrome.

Authors:  Nagwa Abdallah Ismail; Nermeen Salah Eldin Metwaly; Fatma Ahmed El-Moguy; Mona Hassan Hafez; Soha M Abd El Dayem; Tarek Mohamed Farid
Journal:  Indian J Hum Genet       Date:  2010-09

9.  Menarche in primary ovarian insufficiency after a month of hormone replacement therapy: a case report.

Authors:  Biwen Cheng
Journal:  J Med Case Rep       Date:  2021-02-22

Review 10.  Precocious puberty in Turner Syndrome: report of a case and review of the literature.

Authors:  Nicola Improda; Martina Rezzuto; Sara Alfano; Giancarlo Parenti; Pietro Vajro; Claudio Pignata; Mariacarolina Salerno
Journal:  Ital J Pediatr       Date:  2012-10-17       Impact factor: 2.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.